Almirall's solid core business Q1 performance boosted by Growth drivers momentum

Rhea-AI Summary

Almirall, a biopharmaceutical company, reported Q1 2021 financial results, highlighting a 5% increase in Core Net Sales to €215.4 million, aided by one-time positive impacts totaling €16 million. Core EBITDA rose 46% year-on-year to €68 million. Notable products like Ilumetri® saw a 90% sales increase to €17 million, and Seysara® rebounded with 20% growth. The company maintains guidance for mid-single-digit growth in Core Net Sales and EBITDA between €190-210 million. CEO Gianfranco Nazzi expressed confidence in future growth driven by new product launches.

Positive

• Core Net Sales increased by 5% year-on-year to €215.4 million.
• Core EBITDA grew by 46% year-on-year to €68 million.
• Ilumetri® experienced a 90% increase in sales to €17 million.
• Seysara® showed a 20% year-on-year growth in sales after a slight rebound.
• Successful launch of Klisyri® in the US, promising initial uptake.
• Guidance maintained for mid-single-digit growth in Core Net Sales for 2021.

Negative

• None.

BARCELONA, Spain, May 10, 2021 /PRNewswire/ -- Almirall, S.A. (ALM) the global biopharmaceutical company based in Barcelona, has announced its Q1 2021 financial results.

Summary of results

• Solid Core Q1 performance boosted by Growth Drivers and included some one-time items with positive impact on Net Sales for €16 MM in Q1 2021.
• Core Net Sales* reached €215.4 MM, a 5% year-on-year increase with positive contribution by Growth Drivers and one-offs (includes divestment of a small product in Spain and licensing out income from another product with a combined positive impact on Net Sales of €16 MM in Q1 2021).
• Core EBITDA* increased 46% year-on-year to €68 MM with positive contribution by Growth Drivers and one-time items.
• Normalised net income was €42.2 MM.     
• Net Income reached €29.8MM.
• Good Operating Cash Flow reached €82.0MM.

*Core business excludes AstraZeneca contribution: Deferred Income and Other Income

"The solid results seen in 2020 and also this first quarter 2021 confirm that we are on the right track to strengthen our position in medical dermatology. The priorities now are to drive the mid-term growth of the company. To do this we will be investing in new product launches and ensure they perform successfully and grow the core business"
- Gianfranco Nazzi, CEO.

Positive momentum from our Growth Drivers       

Following a positive start to 2021 and with an expectation that the vaccination programmes will contribute to a return to a more normal environment during the second quarter, the company expects a progressive recovery of the Medical Dermatology business in the second half of 2021.

Ilumetri®, an anti-IL-23 high-affinity humanised monoclonal antibody indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis, had a very strong performance throughout the year despite the impact from Covid with a 90% increase in Net Sales year-on-year to €17 MM. Market share trends remain strong in Germany (IL-23 class capturing 33% of market share of new patients within the biologics) and the product is starting to gain traction in Spain and Italy following virtual launches, and launch in France is also underway. Whilst competition is strong, Ilumetri® has a compelling product profile as the first IL-23 to deliver a dataset with a favourable long-term safety profile through 5 years and good tolerance delivering maintained control for psoriasis patients, and ease of use as the key attributes.

Seysara®, an innovative oral antibiotic derived from tetracycline and specifically designed to treat acne, achieved a slight rebound in the first quarter of 2021 in line with the overall OAB market and following the slow down seen in Q4 2020 from Covid-19. Net Sales c.+20% growth year-on-year. Seysara®'s recovery has been bolstered with the microbiology label update, supporting the new promotional activity and medical education programme.

Klisyri®, a novel, first-in-class microtubule inhibitor indicated for the topical treatment of actinic keratosis (AK) of the face or scalp, was successfully launched in February 2021 in the US. Its launch represents a major step forward in the treatment of AK -the second most common diagnosis made by dermatologists in the United States- due to its convenient 5-day application period, the shortest of any topical treatment for AK, and proven efficacy and safety profile. Initial uptake of Klisyri® in the US was encouraging and we received good feedback from dermatologists and patients. Klisyri® is also awaiting approval in Europe, expected in H1 2021.

Late-stage pipeline with promising potential

The high level readout of the phase 3 clinical trials for Lebrikizumab, an anti-IL13 monoclonal antibody for the treatment of moderate-to-severe atopic dermatitis, is expected in the second half of this year. The company is working with partner Eli Lilly on the launch, expected for 2023. Lebrikizumab has the potential to be a best-in-disease therapy for people living with moderate-to-severe atopic dermatitis.

In February 2021, Almirall announced an agreement with MC2 Therapeutics, which granted Almirall exclusive European rights to market Wynzora® cream for the treatment of plaque psoriasis. Wynzora®, a topical calcipotriene/betamethasone DP combination cream developed using PAD™ formulation technology, received US FDA approval on July 20, 2020, and is currently in pre-registration for psoriasis in Europe. With the addition of this product to its portfolio, Almirall has become the only biopharmaceutical in Europe to offer psoriasis patients multiple innovative treatment options covering the entire spectrum of the disease.

Almirall has also focused on developing Almirallshare, an open innovation R&D platform designed to establish collaborations with universities, research institutions, hospitals, start-ups, and the biopharma industry. Since its launch in 2017, more than 900 scientists have joined the project, and more than 400 proposals have been received. At present, there are eight ongoing collaborative projects with scientific institutions like the University of South Australia.

During the last year, Almirall established strategic collaborations and partnerships to accelerate discovering and developing new therapies in Medical Dermatology. Examples of these agreements are the collaboration with the University of Dundee, which will bring with it the opportunity to develop new therapies based on targeted protein degraders.

Guidance for 2021

Guidance maintained. Core Net Sales mid-single-digit growth, Core EBITDA between €190 - €210 MM which equates to approximately €215 - €235 MM of reported EBITDA.  

Investor Calendar 2021

• H1 2021 Financial Results – 26^th July 2021

 

View original content:http://www.prnewswire.com/news-releases/almiralls-solid-core-business-q1-performance-boosted-by-growth-drivers-momentum-301287223.html

SOURCE Almirall, S.A.

FAQ

What were Almirall's Q1 2021 financial results?

Almirall reported Q1 2021 Core Net Sales of €215.4 million, a 5% increase year-on-year, with Core EBITDA rising 46% to €68 million.

How did Ilumetri® perform in Q1 2021?

Ilumetri® sales increased by 90% year-on-year, reaching €17 million in Q1 2021.

What is Almirall's guidance for 2021?

Almirall maintained guidance for mid-single-digit growth in Core Net Sales and Core EBITDA between €190-210 million for 2021.

When will Almirall announce its H1 2021 financial results?

Almirall is set to announce its H1 2021 financial results on July 26, 2021.

What contributed to Almirall's strong Q1 2021 performance?

The strong performance was boosted by Growth Drivers and included one-time positive impacts totaling €16 million.